A Gringeri, E Santagostino, M Muça-Perja, P M Mannucci, J F Zagury, B Bizzini, A Lachgar, M Carcagno, J Rappaport, M Criscuolo, W Blattner, A Burny, R C Gallo, D Zagury
{"title":"HIV-1 Tat类毒素在免疫功能低下的HIV-1感染患者中的安全性和免疫原性","authors":"A Gringeri, E Santagostino, M Muça-Perja, P M Mannucci, J F Zagury, B Bizzini, A Lachgar, M Carcagno, J Rappaport, M Criscuolo, W Blattner, A Burny, R C Gallo, D Zagury","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients.</p><p><strong>Method: </strong>The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromised individuals (500-200 CD4+ cells/mm3).</p><p><strong>Results: </strong>Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro.</p><p><strong>Conclusion: </strong>These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.</p>","PeriodicalId":80032,"journal":{"name":"Journal of human virology","volume":"1 4","pages":"293-8"},"PeriodicalIF":0.0000,"publicationDate":"1998-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.\",\"authors\":\"A Gringeri, E Santagostino, M Muça-Perja, P M Mannucci, J F Zagury, B Bizzini, A Lachgar, M Carcagno, J Rappaport, M Criscuolo, W Blattner, A Burny, R C Gallo, D Zagury\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients.</p><p><strong>Method: </strong>The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromised individuals (500-200 CD4+ cells/mm3).</p><p><strong>Results: </strong>Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro.</p><p><strong>Conclusion: </strong>These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.</p>\",\"PeriodicalId\":80032,\"journal\":{\"name\":\"Journal of human virology\",\"volume\":\"1 4\",\"pages\":\"293-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of human virology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of human virology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:为了对抗HIV-1毒素细胞外Tat对未感染免疫细胞的有害作用，我们开发了一种新的抗HIV-1疫苗策略，使用灭活但具有免疫原性的Tat (Tat类毒素)。该类毒素已在血清阳性患者中进行了安全性和免疫原性试验。方法:对14例无症状但生物免疫功能低下(500-200 CD4+细胞/mm3)的hiv -1感染患者进行了Seppic Isa 51油佐剂中Tat类毒素制剂的I期疫苗临床试验。结果:经8次注射，无临床缺陷。所有患者对Tat均表现出抗体(Ab)应答，部分患者体内皮肤试验和体外t细胞增殖评价为细胞介导免疫(CMI)。结论:这些结果为hiv -1感染者接种Tat类毒素疫苗的安全性和效力提供了初步证据。
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
Objectives: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HIV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients.
Method: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromised individuals (500-200 CD4+ cells/mm3).
Results: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro.
Conclusion: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
